share_log

東陽光長江藥業：補充公告 盈利預喜

HEC CJ PHARM: SUPPLEMENTAL ANNOUNCEMENT POSITIVE PROFIT ALERT

香港交易所 ·  Mar 15 10:40
Summary by Moomoo AI
宜昌東陽光長江藥業股份有限公司（「東陽光長江药业」）於2024年3月12日發布盈利預喜，預期截至2023年12月31日止年度的除稅前溢利及歸母淨利潤將有所增加。此外，公司提及了2024年3月8日的公告，關於可能通過換股方式吸收合併的情況（「可能合併」）。由於盈利預告在可能合併的要約期內公佈，按照收購守則規則10，公司的財務顧問及核數師或會計師需就盈利預告作出報告。然而，公司需在可行的情況下盡快發布盈利預告，因此在時間上存在困難。公司已採取適當措施，並將遵守收購守則的規定。公司警告股東及潛在投資者，盈利預告未經審計且未達到收購守則規則10的準則，因此在依賴盈利預告時應審慎行事。公司也提醒，可能合併或上市並無保證會實現或完成，且任何討論可能不會導致公司私有化或撤銷上市。股東及潛在投資者應謹慎買賣股份。
宜昌東陽光長江藥業股份有限公司（「東陽光長江药业」）於2024年3月12日發布盈利預喜，預期截至2023年12月31日止年度的除稅前溢利及歸母淨利潤將有所增加。此外，公司提及了2024年3月8日的公告，關於可能通過換股方式吸收合併的情況（「可能合併」）。由於盈利預告在可能合併的要約期內公佈，按照收購守則規則10，公司的財務顧問及核數師或會計師需就盈利預告作出報告。然而，公司需在可行的情況下盡快發布盈利預告，因此在時間上存在困難。公司已採取適當措施，並將遵守收購守則的規定。公司警告股東及潛在投資者，盈利預告未經審計且未達到收購守則規則10的準則，因此在依賴盈利預告時應審慎行事。公司也提醒，可能合併或上市並無保證會實現或完成，且任何討論可能不會導致公司私有化或撤銷上市。股東及潛在投資者應謹慎買賣股份。
YICHANG EAST SUNSHINE CHANGJIANG PHARMACEUTICAL CO., LTD. (“EAST SUNSHINE CHANGJIANG PHARMACEUTICALS”) ISSUED A PROFIT FORECAST ON MARCH 12, 2024. IT IS EXPECTED THAT PRE-TAX PROFIT AND NET MATERNITY PROFIT FOR THE YEAR ENDED DECEMBER 31, 2023 WILL INCREASE. In addition, the Company mentioned the announcement of March 8, 2024 regarding the possibility of absorption of the Merger (the “Possible Merger”) by way of exchange. Since the earnings announcement is published within the proposed period of a possible merger, the Company's financial advisors and auditors or accountants are required to report on the earnings announcement in accordance with Rule 10 of the Acquisition Code. However, companies need to issue profit warnings as soon as possible, so there are difficulties in time. The Company has taken appropriate...Show More
YICHANG EAST SUNSHINE CHANGJIANG PHARMACEUTICAL CO., LTD. (“EAST SUNSHINE CHANGJIANG PHARMACEUTICALS”) ISSUED A PROFIT FORECAST ON MARCH 12, 2024. IT IS EXPECTED THAT PRE-TAX PROFIT AND NET MATERNITY PROFIT FOR THE YEAR ENDED DECEMBER 31, 2023 WILL INCREASE. In addition, the Company mentioned the announcement of March 8, 2024 regarding the possibility of absorption of the Merger (the “Possible Merger”) by way of exchange. Since the earnings announcement is published within the proposed period of a possible merger, the Company's financial advisors and auditors or accountants are required to report on the earnings announcement in accordance with Rule 10 of the Acquisition Code. However, companies need to issue profit warnings as soon as possible, so there are difficulties in time. The Company has taken appropriate measures and will comply with the Acquisition Code. The Company cautions shareholders and potential investors that the profit forecast is unaudited and does not meet the criteria of Rule 10 of the Takeover Code, so it should exercise caution when relying on profit warnings. The Company is also reminded that there is no guarantee that a merger or listing will be consummated or completed, and any discussion may not result in the Company's privatization or withdrawal from the listing. Shareholders and potential investors should buy and sell shares with caution.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more